OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity.
OPK-88003 is a dual GLP-1/glucagon receptor agonist. OPKO previously reported topline data for the modified intent to treat population – patients that received at least one dose of OPK-88003 and had one post-baseline evaluation. These patients demonstrated a reduction in HbA1c from baseline at 30 weeks of 1.30% in the treated group, compared with 0.09% in the placebo group.
Further analysis of the per protocol population – patients treated with OPK-88003 for at least 26 weeks – showed a more pronounced decrease in HbA1c and an increase in weight loss. In this group, patients treated with OPK-88003 experienced a 1.47% decline in HbA1c, compared with 0.25% in the placebo group.
OPKO is planning to evaluate OPK-88003 in a Phase 3 trial in Type 2 diabetes and obesity.
